Biomerica

Biomerica EBIT per Share

The EBIT per Share of Biomerica (BMRA) as of Oct 26, 2026 is -1.61 USD. In the previous year, EBIT per Share was -1.77 USD — a change of -8.62% (higher).

EBIT per Share

-1.61USD

YoY

-8.62%

Last updated:

EBIT per Share of Biomerica is 2026 -1.61 USD. EBIT per Share of Biomerica was 2025 -1.77 USD. It decreases by -8.62% higher compared to the previous year.

The Biomerica EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2019
-0.25 USD
Jan 1, 2020
-0.20 USD
Jan 1, 2021
-0.60 USD
Jan 1, 2022
-0.34 USD
Jan 1, 2023
-0.43 USD
Jan 1, 2024
-0.37 USD
Jan 1, 2025
-1.77 USD
Jan 1, 2026
-1.61 USD
The Biomerica EBIT per Share history
YEAREBIT per ShareYoY
-1.61USD-8.62%
-1.77USD+375.00%
-0.37USD-13.39%
-0.43USD+27.43%
-0.34USD-43.42%
-0.60USD+191.40%
-0.20USD-16.84%
-0.25USD+50.30%
-0.16USD+45.94%
-0.11USD+10.96%
-0.10USD+14.24%
-0.09USD+49.47%
-0.06USD-183.74%
0.07USD+3.27%
0.07USD-457.79%
-0.02USD-65.08%
-0.05USD-246.61%
0.04USD-51.44%
0.08USD+8.17%
0.07USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biomerica Stock analysis

What does Biomerica do? Biomerica, Inc. generates revenue through the development, manufacture, and marketing of medical diagnostic products for early detection and monitoring of chronic diseases. The company sells diagnostic test kits to clinical laboratories and point-of-care markets, analyzing blood, urine, or fecal specimens to measure specific bacteria, hormones, antibodies, antigens, or other substances. Its flagship product, InFoods IBS, offers diagnostic-guided therapy to identify patient-specific foods that may alleviate Irritable Bowel Syndrome symptoms when removed from the diet. The diagnostic test kits are used by clinical laboratories and point-of-care facilities to detect diseases through specimen analysis. InFoods IBS targets physicians seeking personalized dietary solutions for IBS patients, allowing them to identify foods that improve symptoms when eliminated. Biomerica focuses on chronic disease management with products designed for early detection and monitoring in both laboratory and point-of-care settings. Biomerica's revenue streams include sales of diagnostic test kits to clinical laboratories and point-of-care markets, as well as the InFoods IBS diagnostic-guided therapy product. The company serves healthcare providers and physicians who utilize these tools for patient diagnosis and treatment planning, particularly in managing chronic conditions like IBS through dietary adjustments. Biomerica is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biomerica stock

EBIT per Share of Biomerica is -1.61 USD in 2026.

EBIT per Share of Biomerica changed from -1.77 USD to -1.61 USD, representing a -8.62% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Biomerica since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Biomerica

All Key Metrics — Biomerica